Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds like IPIX’s current plan is to (avoid investments of time and financial resources required for clinical trials of Brilacidin) and to (give more capital away for other investment opportunities.)
Sucks to be a bagholder at a penny. IPIX drops our investment in Kevetrin and adds lightsabers. No telling what we will be invested in next month.
Ok. A few responses, but no one supporting more capital outflow to private companies in Israel.
Any shareholders support Management’s Plan of Operation for 2023?
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
Source dated 11/10/22
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Do you support the company giving away more of our capital to private companies in Israel in 2023 for a stake in those companies?
Do you support the company giving away more of our capital to private companies in Israel in 2023?
However u’d like it phrased. Our, their, my, your. Whatever suits u. The question remains.
Any shareholders here support the company giving away more of our capital to private companies in Israel in 2023?
Of course.
Yes she does.
Lmao. Drop the mic.
I find it hilarious she has a LinkedIn page and chose not to list the name of the company she “works” for.
“The message I got was the search for answers and solutions around Covid remains active.”
It’s clear from the preclinical studies and clinical trial that followed, along with IPIX’s current management plan, that Brilacidin isn’t the answer or solution.
I had Covid and was asymptomatic. Vaccinated. Actually enjoyed the experience. Had a ton of energy from what I suspect was increased heart rate. COVID is nothing more than the cold/flu for most at this point.
The only way I knew I had it was one person in our office had flu like symptoms so everyone tested. 4 people positive. Only 1 person had symptoms.
Based on the filings, Leo and Jane made somewhere in the neighborhood of $20k in compensation this week (and every week) thanks to all the bag holders.
Ads bring awareness. What’s not to like? New investors, please join us in our misery as our brokerage accounts approach zero.
You’re suggesting the authors are buying? LOL. The authors of this one didn’t fair so well. https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1
Here’s a common theme from the dish studies…
Competing Interest Statement
Funding: George Mason University, with identified lead researcher Aarthi Narayanan, received financial support from Innovation Pharmaceuticals Inc. to conduct research on brilacidin's antiviral properties. Conflicts of Interest: Warren Weston serves as a consultant for Innovation Pharmaceuticals Inc. Jane A. Harness is an employee of Innovation Pharmaceuticals Inc.
Same same but different. No one is buying it. https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1
And the content came from the company w/o disclaimer which goes against the info u provided. Why don’t u prove they didn’t pay for it.
They got paid I assure u.
Yippie… That should lower the price by another 20%.
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
Source: Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Oh does it ever!
Doesn’t look like anyone is buying it.
.009’s are on deck.
If Brilacidin was worth more than the CEO’s paycheck, it would have been picked up by Pharma long ago.
Below you’ll find a link to the filings and most recent 10Q. Search for key words, like nasal and funding.
You’ll find ZERO results for Nasal.
You’ll also find 1.) the company doesn’t have financial resources to advance Brilacidin into clinical trials and 2.) the company plans to AVOID such investments of time and financial resources.
In the CEO’s own words from Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Isn’t that how they pay their taxes?
$940,000/yr in salary/bonuses. Not to mention stock/option awards! Dilution to sustain these type compensations near a penny will keep driving the stock price lower and lower.
2022 recap - the CEO received compensation of approx. $11,000/week from the company and based on the filings didn’t do jack shit except give away $4M to a foreign private company for a product that may or may not ever come to fruition. And then there’s Jane….
Looks like IPIX will be under a penny in 2023.
I can’t believe it!
Somewhat. Thank you.
As predicted. There will be another zero in there soon enough.